Guidelines for the Economic Analysis of IDB-Funded Projects

Escalating healthcare costs and increasing demands on healthcare systems have increased the need for efficient resource allocation. Pharmacoeconomics is a vital field that quantifies and compares the value of therapeutic drugs or treatments. It provides a systematic framework for decision-makers in the pharmaceutical industry, government, and private sectors to optimize healthcare delivery and spending. This review aimed to explore the role of pharmacoeconomic models in assessing the economic and clinical value of therapies. It emphasizes the importance of cost-effectiveness, cost-utility, cost-benefit, and cost-minimization analyses in balancing costs with outcomes and guiding healthcare resource allocation. Pharmacoeconomic methodologies focus on assessing the costs, processes, and outcomes associated with therapeutic interventions. Key methods include cost-minimization, costeffectiveness, cost-utility, and cost-benefit analyses. These approaches are critical in regulatory compliance, reimbursement decisions, cost assessments, and sustaining pharmaceutical models. This review reveals that pharmacoeconomic approaches such as Cost-Effectiveness Analysis (CEA), Cost-Utility Analysis (CUA), and Cost-Benefit Analysis (CBA) are widely used to guide healthcare policy decisions, particularly in resource-constrained settings. CEA is the most commonly applied method due to its simplicity, while CUA is gaining traction in advanced policy frameworks like Health Technology Assessment (HTA). In India, pharmacoeconomic research is emerging but faces barriers such as limited access to real-world data, the absence of national reimbursement systems, and high out-of-pocket costs. Innovative methods like machine learning and pharmacogenomics are being explored to improve the relevance and precision of these evaluations. While pharmacoeconomic models offer valuable insights for healthcare decisionmaking, their real-world impact is limited by inconsistencies in data quality and variations in implementation standards. In India, fragmented governance, low public health spending, and a lack of coordination among stakeholders further hinder effective application. Addressing systemic challenges-such as establishing interoperable data systems, standard treatment guidelines, and equitable healthcare access-is crucial. Tailored approaches, including localized utility values and digital health initiatives, are essential to make pharmacoeconomics a practical and influential tool in policy formulation and resource allocation in India and similar settings. Pharmacoeconomic studies evaluate clinical efficacy, adverse effects, and production costs while incorporating perspectives from patients, providers, payers, and communities. For India, unique challenges such as limited rural healthcare access, infrastructure disparities, and high out-of-pocket expenses necessitate tailored adaptations. Strategies such as integrating accessibility metrics, localized data, equity considerations, preventive care, tiered pricing, and public-private partnerships can enhance healthcare delivery. Pharmacoeconomic models are essential for improving health outcomes, ensuring equitable resource allocation, and addressing the diverse needs of India.

Chapter 16 gives an overview of cost-effectiveness and cost-benefit analysis. Every year millions of dollars are spent on food and nutrition intervention programs that are designed to improve health. Given money can always be spent in many different ways leads to a natural question: How effective was the program, relative to how much it cost? There are two standard approaches to answering this question: a cost effectiveness analysis and a cost benefit analysis. The chapter covers the main questions that must be answered in doing either a cost effectiveness or cost benefit analysis. The main formulas in each approach are presented. The pros and cons of each approach are discussed. A hypothetical nutrition intervention program is carried throughout to provide context for the discussion.

The purpose of this paper is to provide a brief overview of economic analysis methods used in estimating the costs and benefits of public health programs and systematically review the application of these methods to the National Breast and Cervical Cancer Early Detection Program (NBCCEDP). Published literature on economic analyses of the NBCCEDP was systematically reviewed. The Consensus on Health Economic Criteria checklist was used to assess methodological quality of the included studies. Methods available for economic analysis of public health programs include program cost, cost-effectiveness, cost-utility, cost-benefit analysis, and budget impact analysis. Of these, program cost analysis, cost-effectiveness analysis, and cost-utility analysis have been applied to the NBCCEDP in previously published literature. While there have been multiple program cost analyses, there are relatively fewer cost-effectiveness and cost-utility studies and no cost-benefit and budget impact analysis studies to evaluate the NBCCEDP. Addressing these gaps will inform implementation of effective public health programs with equitable resource allocation to all population subgroups.

Cost-effectiveness analysis (CEA) is the main way that economic evaluations are carried out in the health care field. However, CEA has limited validity in deciding whether any health care evaluation is socially worthwhile and hence justifies funding. Cost-Benefit Analysis (CBA) is the economic evaluation method that should be used to help decide what to invest in when the objective is to record the impact on everyone in society. Cost-utility analysis (CUA), which has its roots in CEA, can be converted into CBA under certain circumstances that are not general. In this article, the strengths and weaknesses of CEA relative to CBA are analyzed in stages, starting in its most classical form and then proceeding via CUA to end up as CBA. The analysis takes place mainly in the context of five actual dementia interventions that have already been found to pass a CBA test. The CBA data is recast into CEA and CUA terms in tabular form in order that the contrast been CEA and CBA is most transparent. We find that how much of the fixed budget that is used up to fund other alternatives determines how much is left over to fund the particular intervention one is evaluating.

I am glad to have the opportunity to respond to the fine paper by Professors Smith and Sach (2009). They raise both foundational questions concerning the justification of contingent valuation studies in the health policy area, and important implementation questions concerning the appropriate design of such studies. I will focus my attention on the question of justification. The debate about contingent valuation in health policy is part and parcel of the debate between those who favour cost–benefit analysis (CBA), and those who favour cost-effectiveness analysis (CEA) (Adler, 2006: 1–17). CBA values all well-being impacts, including health and longevity, in dollar terms, and aggregates. Technically, CBA evaluates policies by aggregating willingness-to-pay/willingnessto-accept amounts (WTPs). Standard techniques for estimating WTPs are twofold: revealed preference techniques, which estimate them based on market behaviour (such techniques have been widely used to estimate WTPs for fatality risk reduction, known as the ‘value of statistical life’); and survey techniques. ‘Contingent valuation’ is just the technical term for such survey techniques. CEA, like CBA, values non-health impacts (‘costs’) in dollar terms; but it values health impacts on some non-monetary ‘effectiveness’ scale. It then examines the incremental cost-effectiveness ratios of policies in order to determine which policies to adopt. Techniques for estimating WTPs for health impacts – in particular, contingent valuation studies of health effects – therefore have no direct role in CEA. So one can take a first crack at the question of justification for health care contingent valuation studies by asking, should CBA or CEA be used to evaluate health policies? Now, this question is often seen in the health policy literature as just a choice between ‘welfarism’ and ‘extrawelfarism’. Welfarism favours CBA, extrawelfarism favours CEA – or so it is often assumed. I think the assumption is doubly mistaken. First – although I cannot pursue the point at length here – I think that CEA should be seen by extrawelfarists as little better than CBA. To adequately develop the point, we would need to get clear about the content of extrawelfarism – a large task (Brouwer et al., 2008).

Cost-effectiveness analyses in gynecologic oncology: methodological quality and trends

The subject-matter of the research is economic analysis in public law. This method evaluates both costs and benefits of the regulatory measures. When assessing the alternatives, the judges in public litigation take into account their side effects. If an economically effective alternative is found, it should be ensured that it imposes a minimal burden on the rightholder or the costs to third parties.The purpose of the research is to argue that the cost-benefits analysis should be limited primarily to the economic field. Otherwise, personal, political, and social rights can be conferred with the properties of goods (commodification).The methodology of research is based on approaches of school “law and economics”. Economic analysis of law makes it possible to construct a scale of constitutional values, albeit not uncontroversial, but universal. This scale offers the important advantage of introducing proportionality for seemingly disparate individual freedoms and public interests. The introduction of material and financial scales, including compensation even for irreparable intangible goods, represents a better solution than the available alternatives.The main results of the research and the scope of their application. The above-mentioned method consists of assessing the costs and benefits both for the right-holders and for achieving the common good. It is necessary to analyse the costs and benefits of the challenged legal provision to individuals. Then, the governmental costs incurred in using alternative means should be reviewed. The public authorities should not incur excessive organisational or financial costs from a legal alternative that is humane to the individual. Due to the objective constraint on public resources, judges take into account future budgetary expenditures.In constitutional adjudication and administrative litigation, cost-benefit analysis is most effective in the economic sphere. It is easier to ensure the measurability of judicial review, usually in monetary or other material terms. The preparatory works, including the financial and economic justification of draft laws or regulations, may serve as an informational source in reviewing the legislative provisions and administrative acts which entail material costs. The cost-benefit analysis is applicable to non-material sphere. Although such costs generated by regulators are often difficult to assess in public law. A cost-benefit analysis is possible even in the political sphere. At the same time the judges usually restrain itself from assessing the political expediency of legislative decisions and administrative actions. Conclusions. There is a danger of economic analysis being abused in public law. The disadvantages of using this methodology include the possible devaluation of values which are essential for democracy. The abstract common good and reducing public expenditure will prevail over individual freedoms.

This paper investigates the application of cost-effectiveness and cost-benefit analysis in Pharmaceutical manufacturing. As healthcare costs rise and resources become increasingly limited, the need for effective allocation of resources in drug development distribution and strategies is paramount. Cost-effectiveness analysis (CEA) evaluates the relative costs and outcomes of various attacks, aiding decision-makers in deciding the most effective use of money. Meanwhile, a cost-benefit study (CBA) goes further, judging the costs against the benefits, often in financial conditions, to determine the overall societal prosperity impact. Both methods offer priceless intuitions into the economic associations of drug interventions, influencing policy decisions, valuing procedures, and healthcare resource distribution. However, challenges lie, in containing the complexities of determining indefinite benefits, giving reason for unending impacts, and reconciling disagreeing views on worth. Furthermore, the ethical concerns of prioritizing certain mediations over possible choices based alone on economic determinants require painstaking traveling. This paper argues these challenges and suggests strategies to embellish the use of cost-effectiveness and cost-benefit analysis in pharmaceuticals, guaranteeing an impartial approach to essential situations while optimizing societal prosperity.

Cost-effectiveness and cost-benefit analysis of worksite nutrition programs

To determine whether published cost-effectiveness and cost-benefit analyses have adhered to basic analytic principles. Structured methodologic review of published articles. Seventy-seven articles published either from 1978 to 1980 or from 1985 to 1987 in general medical, general surgical, and medical subspecialty journals. Articles were reviewed to assess the use and reporting of six fundamental principles of analysis. These principles were derived by reviewing widely cited textbooks and articles describing the methods for performing economic analyses and by selecting the methods universally recommended. Overall performance was only fair. Three articles adhered to all six principles, and the median number of principles to which articles adhered was three. Among the problems noted were failure to make underlying assumptions explicit and, therefore, verifiable, and failure to test assumptions with sensitivity analyses. No improvement in performance was observed between 1978 and 1987. Articles in general medical journals, however, were more likely to use analytic methods appropriately than articles in the general surgical or medical subspecialty literature. Greater attention should be devoted to ensuring the appropriate use of analytic methods for economic analyses, and readers should make note of the methods used when interpreting the results of economic analyses.

Data Needs for Economic Evaluations of Screening in Pediatric Primary Care: A Research Framework.

On the possibility of a bridge between CBA and CEA: comments on a paper by Dolan and Edlin

Any new technology that promises significant costs as well as potential benefits generates considerable interest. Such innovations bring into bold relief the fundamental problem of achieving maximal medical benefits while efficiently and equitably allocating scarce resources (II). Two tools that decision makers can use to assess the benefits and costs of implementing new technologies are cost- benefit analysis (CBA) and cost-effectiveness analysis (CEA). One technology that seems especially appropriate for the application of CBA and CEA is nuclear magnetic resonance (NMR) imaging.

Revisión sistemática de estudios de evaluación económica sobre vacunas antirrotavirus

Health economic analyses have become important to healthcare systems worldwide. No studies have previously examined South America's contribution in this area. To survey the literature with the purpose of reviewing, quantifying, and assessing the quality of published South American health economic analyses. A search of MEDLINE (1990-December 2004), EMBASE (1990-December 2004), International Pharmaceutical Abstracts (1990-December 2004), Literatura Latino-Americana e do Caribe em Ciências da Saúde (1982-December 2004), and Sistema de Informacion Esencial en Terapéutica y Salud (1980-December 2004) was completed using the key words cost-effectiveness analysis (CEA), cost-utility analysis (CUA), cost-minimization analysis (CMA), and cost-benefit analysis (CBA); abbreviations CEA, CUA, CMA, and CBA; and all South American country names. Papers were categorized by type and country by 2 independent reviewers. Quality was assessed using a 12 item checklist, characterizing scores as 4 (good), 3 (acceptable), 2 (poor), 1 (unable to judge), and 0 (unacceptable). To be included in our investigation, studies needed to have simultaneously examined costs and outcomes. We retrieved 25 articles; one duplicate article was rejected, leaving 24 (CEA = 15, CBA = 6, CMA = 3; Brazil = 9, Argentina = 5, Colombia = 3, Chile = 2, Ecuador = 2, 1 each from Peru, Uruguay, Venezuela). Variability between raters was less than 0.5 point on overall scores (OS) and less than 1 point on all individual items. Mean OS was 2.6 (SD 1.0, range 1.4-3.8). CBAs scored highest (OS 2.8, SD 0.8), CEAs next (OS 2.7, SD 0.7), and CMAs lowest (OS 2.0, SD 0.5). When scored by type of question, definition of study aim scored highest (OS 3.0, SD 0.8), while ethical issues scored lowest (OS 1.5, SD 0.9). By country, Peru scored highest (mean OS 3.8) and Uruguay had the lowest scores (mean OS 2.2). A nonsignificant time trend was noted for OS (R2 = 0.12; p = 0.104). Quality scores of health economic analyses articles published in South America were rated poor to acceptable and lower than previous research from other countries. Thus, efforts are needed to improve the reporting quality of these analyses in South America. Future research should examine the region's level of expertise and educational opportunities for those in the field of health economics.